Brokerages Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) PT at $35.71

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) has received an average recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $35.71.

A number of analysts recently issued reports on DAWN shares. Needham & Company LLC upped their target price on Day One Biopharmaceuticals from $32.00 to $33.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th. Wedbush reiterated an “outperform” rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research note on Thursday, August 1st. JPMorgan Chase & Co. decreased their target price on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Finally, Piper Sandler restated an “overweight” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a research report on Monday, July 8th.

Day One Biopharmaceuticals Trading Up 3.7 %

DAWN stock opened at $14.83 on Wednesday. The stock has a market cap of $1.30 billion, a P/E ratio of -5.91 and a beta of -1.51. Day One Biopharmaceuticals has a twelve month low of $9.67 and a twelve month high of $18.07. The company’s 50 day moving average is $13.93 and its two-hundred day moving average is $14.39.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings results on Tuesday, July 30th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.70. The company had revenue of $8.19 million during the quarter, compared to analysts’ expectations of $0.90 million. On average, equities research analysts predict that Day One Biopharmaceuticals will post -1.68 earnings per share for the current year.

Insider Transactions at Day One Biopharmaceuticals

In related news, CFO Charles N. York II sold 2,633 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $14.00, for a total value of $36,862.00. Following the sale, the chief financial officer now directly owns 232,485 shares in the company, valued at $3,254,790. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, insider Samuel C. Blackman sold 2,232 shares of the firm’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $14.00, for a total value of $31,248.00. Following the completion of the sale, the insider now owns 1,127,535 shares in the company, valued at $15,785,490. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Charles N. York II sold 2,633 shares of the company’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $14.00, for a total transaction of $36,862.00. Following the transaction, the chief financial officer now owns 232,485 shares in the company, valued at $3,254,790. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 48,748 shares of company stock valued at $689,072. Corporate insiders own 8.40% of the company’s stock.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Institutional investors have recently modified their holdings of the company. Quintet Private Bank Europe S.A. increased its stake in Day One Biopharmaceuticals by 43.2% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock valued at $48,000 after purchasing an additional 1,000 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Day One Biopharmaceuticals in the second quarter valued at $113,000. Point72 DIFC Ltd acquired a new position in shares of Day One Biopharmaceuticals during the 2nd quarter worth $124,000. Hsbc Holdings PLC acquired a new position in shares of Day One Biopharmaceuticals during the 2nd quarter worth $163,000. Finally, SteelPeak Wealth LLC purchased a new stake in shares of Day One Biopharmaceuticals in the 2nd quarter worth about $218,000. Hedge funds and other institutional investors own 87.95% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.